KPTI Stock Overview
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Karyopharm Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.47 |
52 Week High | US$4.87 |
52 Week Low | US$0.62 |
Beta | 0.0025 |
1 Month Change | 15.75% |
3 Month Change | 87.60% |
1 Year Change | -58.36% |
3 Year Change | -87.54% |
5 Year Change | -73.27% |
Change since IPO | -90.84% |
Recent News & Updates
Recent updates
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%
Feb 23Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Feb 05Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified
Apr 17Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 17Karyopharm: Market Is Overlooking Growth
Oct 07Karyopharm Therapeutics Q2 2022 Earnings Preview
Aug 03Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU
Jul 20Karyopharm: Another 2 Year Wait For Data
May 05Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates
Feb 19Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position
Dec 04Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls
Sep 16Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Aug 07Shareholder Returns
KPTI | US Biotechs | US Market | |
---|---|---|---|
7D | -0.7% | -2.1% | 0.5% |
1Y | -58.4% | 9.7% | 29.0% |
Return vs Industry: KPTI underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: KPTI underperformed the US Market which returned 28.4% over the past year.
Price Volatility
KPTI volatility | |
---|---|
KPTI Average Weekly Movement | 19.0% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KPTI's share price has been volatile over the past 3 months.
Volatility Over Time: KPTI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 325 | Richard Paulson | https://www.karyopharm.com |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Karyopharm Therapeutics Inc. Fundamentals Summary
KPTI fundamental statistics | |
---|---|
Market cap | US$169.15m |
Earnings (TTM) | -US$143.10m |
Revenue (TTM) | US$146.03m |
1.2x
P/S Ratio-1.2x
P/E RatioIs KPTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KPTI income statement (TTM) | |
---|---|
Revenue | US$146.03m |
Cost of Revenue | US$4.94m |
Gross Profit | US$141.09m |
Other Expenses | US$284.19m |
Earnings | -US$143.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.24 |
Gross Margin | 96.62% |
Net Profit Margin | -97.99% |
Debt/Equity Ratio | -222.7% |
How did KPTI perform over the long term?
See historical performance and comparison